How Mainz benefits from the vaccine boom

Mainz The rapid rise of the biotech company Biontech will bring the German tax authorities an expected tax revenue of almost four billion euros this year and give a number of municipalities undreamt-of financial strength. The Rhineland-Palatinate state capital Mainz alone, where Biontech has its headquarters and employs around 1,500 people, is now calculating additional trade tax income of a good billion euros for 2021.

Mainz should thus rise to the circle of the wealthiest German cities. Cities like Marburg and Idar-Oberstein, where Biontech also produces vaccines and preliminary products, should also benefit greatly.

Thanks to the strong demand for its corona vaccine, the biotech company increased its sales in the first nine months of the year to EUR 13.4 billion and its pre-tax profit to EUR 10.3 billion, as announced on Tuesday. The company reports the tax expense for the period at 3.2 billion euros and this is likely to be due almost exclusively in Germany.